Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) An ophthalmic solution comprising [[0.005]] 0.001 to 0.01 % (W/V) latanoprost as an active ingredient, wherein the latanoprost is stabilized to be stored at room temperature by ~~at least one means selected from the following~~ [[1)]] ~~and~~ [[2):]]

~~1)~~ adjusting the pH of the solution to 5.0 to 6.25 ~~and~~

~~2) adding~~ [[ε-]] ~~aminocaproic acid to the solution~~.

Claims 2 to 4. (canceled)

Claim 5. (new) The ophthalmic solution as claimed in claim 1, wherein the latanoprost is in a concentration of 0.005% (W/V).

Claim 6. (new) An ophthalmic solution comprising 0.001 to 0.01% (W/V) latanoprost as an active ingredient, wherein the

latanoprost is stabilized to be stored at room temperature by adding ε-aminocaproic acid to the solution.

Claim 7. (new) The ophthalmic solution as claimed in claim 6, wherein the latanoprost is in a concentration of 0.005% (W/V).

Claim 8. (new) The ophthalmic solution as claimed in claim 6, wherein the ε-aminocaproic acid is in a concentration of 0.1 to 2% (W/V).

Claim 9. (new) The ophthalmic solution as claimed in claim 7, wherein the ε-aminocaproic acid is in a concentration of 0.1 to 2% (W/V).

Claim 10. (new) The ophthalmic solution as claimed in claim 6, wherein the ε-aminocaproic acid is in a concentration of 1% (W/V).

Claim 11. (new) The ophthalmic solution as claimed in claim 7, wherein the ε-aminocaproic acid is in a concentration of 1% (W/V).

Claim 12. (new) An ophthalmic solution comprising 0.001 to 0.01% (W/V) latanoprost as an active ingredient, wherein the latanoprost is stabilized to be stored at room temperature by adjusting the pH of the solution to 5.0 to 6.25 and adding ε-aminocaproic acid to the solution.

Claim 13. (new) The ophthalmic solution as claimed in claim 17, wherein the latanoprost is in a concentration of 0.005% (W/V).

Claim 14. (new) The ophthalmic solution as claimed in claim 12, wherein the ε-aminocaproic acid is in a concentration of 0.1 to 2% (W/V).

Claim 15. (new) The ophthalmic solution as claimed in claim 13, wherein the ε-aminocaproic acid is in a concentration of 0.1

to 2% (W/V).

Claim 16. (new) The ophthalmic solution as claimed in claim 12, wherein the ε-aminocaproic acid is in a concentration of 1% (W/V).

Claim 17. (new) The ophthalmic solution as claimed in claim 17, wherein the ε-aminocaproic acid is in a concentration of 1% (W/V).